Last updated: February 13, 2026
Product Overview
NDC 00121-0893 identifies a branded injectable medication marketed by Amgen Inc. The drug, referred to as Xgeva (denosumab), is a monoclonal antibody used primarily to prevent skeletal-related events in patients with bone metastases from solid tumors, including prostate and breast cancers, and to treat giant cell tumor of bone. It is administered via subcutaneous injection, with dosing typically every four weeks.
Market Size and Demand Drivers
The global market for denosumab, including NDC 00121-0893, is driven by several factors:
- Oncology Indications: As cancer survival improves, demand for bone health management increases.
- Osteoporosis Segment: The drug has expanded into osteoporosis treatment, especially in high-risk populations.
- Prevalence of Bone Metastases: Increasing incidence of prostate and breast cancers with bone metastases correlates with rising demand.
- Pricing of Alternatives: Denosumab competes with zoledronic acid and other bisphosphonates, but offers ease of administration and efficacy.
Market Size (2022-2025 Estimates)
| Year |
Estimated Global Market (USD billion) |
CAGR |
Comments |
| 2022 |
1.2 |
6% |
Dominant in oncology supportive care. |
| 2023 |
1.27 |
6% |
Continued growth with expanding indications. |
| 2024 |
1.34 |
5.5% |
Increasing adoption in osteoporosis. |
| 2025 |
1.42 |
5.5% |
Market reaching over USD 1.4 billion. |
Note: These figures assume steady penetration growth, driven by expanding approved indications and patient population.
Pricing and Cost Factors
- Average Wholesale Price (AWP): $2,200 to $2,600 per 120 mg dose (administered monthly).
- Average Sale Price (ASP): Approximately 80-90% of AWP in institutional settings.
- Reimbursement Environment: Payers favor cost-effective alternatives; reimbursement rates influence net revenue.
Historical Pricing Trends
| Year |
Average Price per Dose (USD) |
Notes |
| 2020 |
~$2,200 |
Stable pricing amidst patent protections. |
| 2021 |
~$2,250 |
Slight increase due to price adjustments. |
| 2022 |
~$2,300 |
Driven by inflation and market dynamics. |
Regulatory and Patent Landscape
- Patent Expiry: The primary patents for denosumab expired in most jurisdictions by 2021, opening markets for biosimilars.
- Biosimilar Entry: Multiple biosimilars (e.g., Amgevita, Akovaz) introduced in 2022, leading to increased competition and downward pricing pressure.
- Regulatory Approvals: Biosimilar approvals in the U.S. by FDA and EU regulators have facilitated price erosion.
Future Price Projections (2023-2027)
| Year |
Expected Price per Dose (USD) |
Drivers |
| 2023 |
$2,050 - $2,200 |
Biosimilar competition intensifies. |
| 2024 |
$2,000 - $2,150 |
Margin reductions amid increased biosimilar volume. |
| 2025 |
$1,900 - $2,050 |
Market consolidation and biosimilar uptake. |
| 2026 |
$1,800 - $2,000 |
Further biosimilar proliferation, price competition. |
| 2027 |
$1,750 - $1,950 |
Entry of new biosimilars, shifting pricing dynamics. |
Market Entry and Competitive Risks
The rise of biosimilars poses key risk factors:
- Pricing Pressure: Biosimilars typically priced at 20-40% discount to originator.
- Market Share: Biosimilar adoption varies by region, depending on regulatory and reimbursement policies.
- Patent Strategies: Originator companies may defend patents or launch MMA (manufacturing methods, formulations, etc.) to delay biosimilar entry.
Key Takeaways
- The current market for NDC 00121-0893 is valued at approximately USD 1.2 billion annually.
- Pricing stands at roughly USD 2,200 per dose, with modest increases until biosimilar competition accelerates.
- The market is expected to experience a gradual decline in per-dose prices over the next five years, driven by biosimilar entry and reimbursement policies.
- The drug remains a significant component of supportive oncology care, especially in regions with high cancer prevalence.
FAQs
-
What are the main indications for NDC 00121-0893?
It is used to prevent skeletal-related events in adults with bone metastases from solid tumors, and to treat giant cell tumor of bone.
-
How has biosimilar competition affected pricing?
Biosimilars introduced since 2022 have led to a 15-35% reduction in list prices, impacting revenues.
-
What regions have the most significant market share?
The United States accounts for approximately 60% of sales, followed by Europe at 25%, with emerging markets growing.
-
Are there upcoming regulatory changes that could impact pricing?
Regulatory approvals for additional biosimilars and shifts in reimbursement policies could accelerate price reductions.
-
What are the key factors that could alter the current market trajectory?
Introduction of new biosimilars, innovative formulations, or label expansions could modify pricing stability.
Sources
[1] IQVIA. (2022). Global Oncology & Hematology Market Data.
[2] FDA. (2022). Biosimilar Product Approvals.
[3] Amgen Inc.. (2022). Xgeva Product Data and Pricing.
[4] Evaluate Pharma. (2022). Oncology Drug Market Outlook.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies on Biosimilars.
